Nextvisit vs Wysa
Wysa is a patient-facing chatbot offering CBT, DBT and mindfulness-style self-help, anonymously, with paid human coaching. It sells to individuals, employers, health systems and NHS Talking Therapies. Premium is $74.99 per year by several third-party sources, while the US App Store description lists $99.99. Wysa holds an FDA Breakthrough Device Designation from May 2022 for chronic musculoskeletal pain with depression and anxiety, a designation that stops short of clearance.
Nextvisit is clinician software. It drafts notes for psychiatrists, NPs, therapists and addiction clinicians, signs a BAA with every customer, and requires explicit opt-in before training on patient data. Its co-founder is a practicing psychiatrist.
A psychiatrist, NP or therapist who wants notes drafted has no use for Wysa, and someone seeking anonymous self-help, or an NHS Talking Therapies service, has none for Nextvisit.
Mental health · Reviewed November 2, 2026
When to pick each one
Nextvisit
- Explicit opt-in before training on patient data
- BAA with every customer
- Drafts notes for prescribers and therapists
Wysa
- Premium at $74.99 yearly, third-party sources
- Breakthrough Device Designation, May 2022
- NHS Talking Therapies program
Score
Each row shows points earned of points available under the published rubric.
Nextvisit
33of 100
Wysa
57of 100
| Dimension | Nextvisit | Wysa | Difference |
|---|---|---|---|
| FDA clearance | 0 / 6 | 0 / 6 | 0 |
| HIPAA / SOC2 / BAA | 13 / 13 | 7.8 / 13 | +5.2 |
| EHR integrations (count) | 2.1 / 7 | 0 / 7 | +2.1 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4 | 0 / 4 | 0 |
| Bidirectional write-back | 0 / 2 | 0 / 2 | 0 |
| Peer-reviewed papers | 0 / 14 | 9.8 / 14 | -9.8 |
| RCT / meta-analysis / systematic review | 0 / 6 | 6 / 6 | -6 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 5 / 5 | -2.5 |
| Years in market | 4.2 / 6 | 6 / 6 | -1.8 |
Scroll horizontally to see every column.
Pricing
Nextvisit
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Provider | n/a | n/a | Billed monthly. Annual billing $84 per month ($1,008 per year, "Save 15%"). 250 AI credits (about 200 notes). Start free, no card. |
| Provider+ | n/a | n/a | Billed monthly. Annual billing $169 per month ($2,028 per year). 1,000 AI credits (about 500 notes). Adds AriaMD, custom templates, peer review, EHR push. |
| Enterprise | n/a | n/a | No public price. Talk to sales. SSO, supervision, dedicated CSM. |
| Nextvisit Go | n/a | n/a | For therapists, separate workspace. 100 notes. $42 per month billed annually. 14-day trial, no card. |
Wysa
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Plan | n/a | n/a | Free + ~$74.99/yr Premium. |
Evidence
Nextvisit
No FDA decision, peer-reviewed study or community post in our record.
Wysa
Peer-reviewed
3 PubMed records name Wysa.
- Evaluating and Optimizing Just-in-Time Adaptive Interventions in a Digital Mental Health Intervention (Wysa for Chronic Pain) for Middle-Aged and Older Adults With Chronic Pain: Protocol for a Series of Randomized Trials. (opens in new tab)
- Examining a brief web and longitudinal app-based intervention [Wysa] for mental health support in Singapore during the COVID-19 pandemic: mixed-methods retrospective observational study. (opens in new tab)
- Exploring the Role of App Features in Providing Continuity of Care to Users on a Digital Mental Health Platform (Wysa): Retrospective Mixed Methods Observational Study. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Nextvisit | Wysa |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Osmind, SimplePractice, Kalix | Not specified |
| Founded | 2021 | 2015 |
| HQ | n/a | IN |
Scroll horizontally to see both columns.
Common questions
Open the full mental health comparison
Two distinct markets in one category: provider tools (therapy-scribes, supervision AI, session analytics) and patient tools (CBT chatbots, mood trackers, AI companions). We separated them.